Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Pembrolizumab
Keytruda
Not routinely available
SMC (1087/15)
12/12/2016
Indication
As monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults. This submission relates to use in adults previously treated with ipilimumab.
Therapeutic Area
Malignant disease and immunosuppression
Status Description
Not routinely available as not recommended for use in NHSScotland
Formulation
50mg powder for concentrate for solution for infusion
Comments
None
Link to Advice
Advice Published
12/12/2016
SMC Submission Type
Resubmission
SMC Status
Not recommended